GlassScriptPhysician profile
Khalil Alsoutary
NPI 1619388980
$1,382.72
in general payments reported to CMS, 2019-2025
21 companies · $18.60 in 2025
The $18.60 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.28 · 2021: $663 · 2022: $177 · 2023: $326 · 2024: $166 · 2025: $18.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $492.63 | 2021 | |
| Novo Nordisk INC | $205.25 | 2019-2024 | Ozempic, Rybelsus |
| Insulet Corporation | $138.32 | 2023-2024 | Omnipod |
| Grt US Holding, INC. | $92.24 | 2022 | |
| Dexcom, INC. | $71.31 | 2021-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $50.66 | 2023 | Gvoke Hypopen |
| Abbvie INC. | $44.85 | 2023 | Synthroid |
| Amryt Pharma Holdings LTD | $35.51 | 2023 | Mycapssa |
| Medtronic, INC. | $35.16 | 2021-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $27.99 | 2021-2023 | |
| Tandem Diabetes Care, INC. | $22.63 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $21.12 | 2023 | Senza |
| Antares Pharma, INC. | $19.34 | 2023 | Xyosted, Tlando, Nocdurna |
| Corcept Therapeutics | $19.33 | 2022 | |
| Radius Health, INC. | $18.56 | 2023 | Tymlos |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bigfoot Biomedical INC | $16.41 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.07 | 2022 | |
| Boston Scientific Corporation | $15.50 | 2024 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $15.47 | 2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $12.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalil Alsoutary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.